Prospective, randomised trial of the time dependent antiplatelet effects of 500 mg and 250 mg acetylsalicylic acid i. v. and 300 mg p. o. in ACS (ACUTE)

 

 Buy Article Permissions and Reprints

Summary

Little is known about the onset of action after intravenous or oral administration of acetylsalicylic acid (ASA) in patients with acute coronary syndromes (ACS). The aim of the study was to compare intravenous 250 or 500 mg acetylsalicylic acid (ASA) with oral 300 mg in ASA naïve patients with ACS concerning the onset of antiplatelet effects measured by time dependent thromboxane inhibition. A total of 270 patients with ACS < 24 hours were randomised into one of three treatment arms comprising administration of a single dose of ASA as soon as possible after admission. The primary endpoint was platelet inhibition assessed by measurement of arachidonic acid (AA)-induced platelet thromboxane release (TXB2) 5 minutes (min) after study drug administration. Both 250 mg and 500 mg ASA i. v. inhibited TXB2 formation nearly completely (geometric means: from 581.7 and 573.9 ng/ml at baseline to 3.9 and 3.1 ng/ml at 5 min, respectively) compared to 300 mg oral ASA (geometric means: from 652.0 to 223.7 ng/ml) (p-value, ANCOVA: < 0.0001). Similar results were obtained for inhibition of AA-induced platelet aggregation (Multiplate ASPItest; from means 86.41 and 85.72 U to 23.04 and 20.57 U at 5 min, respectively) compared to 300 mg oral ASA from mean 87.18 to 75.56 U (p-value, ANCOVA: <0.0001). The rate of bleedings was low and comparable between the groups. In summary, the administration of a single dose of 250 or 500 mg ASA IV compared to 300 mg orally is associated with a faster and more complete inhibition of thromboxane generation and platelet aggregation. Bleeding complications were comparable between the groups.

Supplementary Material including a list of institutions where work was performed is available online at www.thrombosis-online.com.

• References

• 1 Hamm CW, Bassand JP, Agewall S. et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999-3054.
  CrossrefPubMedGoogle Scholar
• 2 Yeh RW, Sidney S, Chandra M. et al. Population trends in the incidence and out-comes of acute myocardial infarction. N Engl J Med 2010; 362: 2155-2165.
  CrossrefPubMedGoogle Scholar
• 3 André R, Bongard V, Elosua R. et al. International differences in acute coronary syndrome patient’s baseline characteristics, clinical management and outcomes in Western Europe: the EURHOBOP study. Hear 2014; 100: 1201-1207.
  PubMedGoogle Scholar
• 4 Steg PG, James SK, Atar D. et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569-2619.
  CrossrefPubMedGoogle Scholar
• 5 Jneid H, Anderson JL, Wright RS. et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angine/Non-ST-elev-ation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2012; 126: 875-910.
  CrossrefPubMedGoogle Scholar
• 6 O’Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-e425.
  CrossrefPubMedGoogle Scholar
• 7 Nagelschmitz J, Blunck M, Kraetzschmar J. et al. Pharmacokinetics and pharma-codynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers. Clin Pharmacol Adv Appl 2014; 06: 51-59.
  PubMedGoogle Scholar
• 8 nQuery Advisor 6.01® Copyright 1995–2005. Statistical Solutions Ltd.
  PubMedGoogle Scholar
• 9 Hintze J. PASS 2002. NCSS, LLC. Kaysville, Utah, USA. 2002 www.ncss.com
  PubMedGoogle Scholar
• 10 Lewis Jr. HD., Davis JW, Archibald DG. et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403.
  CrossrefPubMedGoogle Scholar
• 11 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet. 1988; 02: 349-360.
  PubMedGoogle Scholar
• 12 Cairns JA, Gent M, Singer J. et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicentre trial. N Engl J Med 1985; 313: 1369-1375.
  CrossrefPubMedGoogle Scholar
• 13 The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet. 1990; 336: 827-830.
  PubMedGoogle Scholar
• 14 Antithrombotic Trialists’s Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
  CrossrefPubMedGoogle Scholar
• 15 Mehta SR, Tanguay JF, Eikelboom JW. et al. CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogral and hig-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.
  CrossrefPubMedGoogle Scholar
• 16 Freimark D, Matatzky S, Leor J. et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol 2002; 89: 381-385.
  CrossrefPubMedGoogle Scholar
• 17 Abdelnoor M, Landmark K. Infarct size is reduced and the frequency of non-Q-wave myocardial infarctions is increased in patients using aspirin at the onset of symptoms. Cardiology 1999; 91: 119-126.
  CrossrefPubMedGoogle Scholar
• 18 Nordt SP, Clark RF, Castillo EM. et al. Comparison of three aspirin formulations in human volunteers. West J Emerg Med 2011; 12: 381-385.
  CrossrefPubMedGoogle Scholar
• 19 Schwertner HA, McGlasson D, Christopher M. et al. Effects of different aspirin formulations on platelet aggregation times and on plasma salicylate concentrations. Thromb Res 2006; 118: 529-534.
  CrossrefPubMedGoogle Scholar
• 20 Say Y, Kusaka A, Imanishi K. et al. A randomised, quadruple crossover single-blind study on immediate action of chewed and unchewed low-dose acetylsalicylic acid tablets. J Pharm Sci 2011; 100: 3884-3891.
  CrossrefPubMedGoogle Scholar
• 21 Benedek IH, Joshi AS, Pieniaszek HJ. et al. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 1995; 35: 1181-1186.
  CrossrefPubMedGoogle Scholar
• 22 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyser (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Vivas D, Bernardo E, García-Rubira JC. et al. Can resistance to aspirin be reversed after an additional dose? J Thromb Thrombolysis. 2011; 32: 356-361.
  PubMedGoogle Scholar
• 24 Gengo F, Westphal ES, Rainka M. et al. Platelet response to increased aspirin dose in patients with persistent platelet aggregation while treated with aspirin 81 mg. J Clin Pharmacol. 2015 Epub ahead of print.
  PubMedGoogle Scholar
• 25 Nishiyama A, Niikawa O, Mohri H. et al. Timing of anti-platelet effect after oral aspirin administration in patients with sympathetic excitement. Circ J 2003; 67: 697-700.
  CrossrefPubMedGoogle Scholar
• 26 Achenbach S, Szardien S, Zeymer U. et al. Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie (ESC) zur Diagnostik und Therapie des akuten Koronarsyndroms ohne persistierende ST-Streckenhebung. Kardiologe 2012; 06: 283-301.
  CrossrefPubMedGoogle Scholar
• 27 Zeymer U, Kastrati A, Rassaf T. et al. Kommentar zu den Leitlinien der Europäischen Gesellschaft für Kardiologie zur Therapie des akuten Herzinfarktes bei Patienten mit ST-Hebung. Kardiologe 2013; 07: 410-422.
  CrossrefPubMedGoogle Scholar
• 28 Zeymer U, Mochmann HC, Mark B. et al. Double-Blind, Randomised, Prospective Comparison of Loading Doses of 600 mg Clopidogrel Versus 60 mg Prasugrel in Patients With Acute ST-Segment Elevation Myocardial Infarction Scheduled for Primary Percutaneous Intervention. JACC: Cardiovascular Interventions 2014; 08: 147-154.
  PubMedGoogle Scholar
• 29 Husted SE, Kristensen SD, Vissinger H. et al. Intravenous acetylsalicylic acid - dose-related effects on platelet function and fibrinolysis in healthy males. Thromb Haemost 1992; 68: 226-229.
  Article in Thieme ConnectPubMedGoogle Scholar

• Supplementary Material